Literature DB >> 26975400

Evaluating the presence of Toxoplasma gondii in peripheral blood of patients with diverse forms of uveitis.

Rubens N Belfort1,2, Jordan Isenberg3, Bruno F Fernandes1, Sebastian Di Cesare1, Rubens Belfort2, Miguel N Burnier1,2.   

Abstract

The purpose of this study was to evaluate the presence of Toxoplasmosis gondii in samples of peripheral blood from patients with varying etiologies of uveitis. Whole blood from patients with different forms of uveitis was tested for the presence of T. gondii using real-time PCR targeting the well-characterized 529 bp fragment. Extracted DNA was both frozen. Thirty-one patients were included in the current study and grouped as follows: acute toxoplasmosis (n = 10); toxoplasmic retinal scars (n = 9); non-infectious etiologies of uveitis (n = 6); and IgG negative for toxoplasmosis (n = 6). In total, only two patients were shown to have circulating T. gondii in peripheral blood; both of these patients were IgG positive for toxoplasmosis, were receiving immunosuppressive therapy for autoimmune uveitis, and had no clinical features of toxoplasmosis. T. gondii was identified in peripheral blood of some immunosuppressed patients. No other patients, including those with acute toxoplasmosis, had circulating parasites in peripheral blood.

Entities:  

Keywords:  PCR; Toxoplasma gondii; Uveitis

Mesh:

Substances:

Year:  2016        PMID: 26975400     DOI: 10.1007/s10792-016-0221-8

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  23 in total

1.  Comparison of immunoblotting, calculation of the Goldmann-Witmer coefficient, and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis.

Authors:  A Fekkar; B Bodaghi; F Touafek; P Le Hoang; D Mazier; L Paris
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

2.  Comparison of detection methods for Toxoplasma gondii in naturally and experimentally infected swine.

Authors:  Dolores E Hill; Sreekumar Chirukandoth; J P Dubey; Joan K Lunney; H Ray Gamble
Journal:  Vet Parasitol       Date:  2006-07-03       Impact factor: 2.738

3.  A follow-up study of Toxoplasma gondii infection in southern Brazil.

Authors:  C Silveira; R Belfort; C Muccioli; M T Abreu; M C Martins; C Victora; R B Nussenblatt; G N Holland
Journal:  Am J Ophthalmol       Date:  2001-03       Impact factor: 5.258

4.  Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families.

Authors:  C Silveira; R Belfort; M Burnier; R Nussenblatt
Journal:  Am J Ophthalmol       Date:  1988-09-15       Impact factor: 5.258

5.  The genotype of Toxoplasma gondii strains causing ocular toxoplasmosis in humans in Brazil.

Authors:  Adriana Lima Vallochi; Cristina Muccioli; Maria Cristina Martins; Cláudio Silveira; Rubens Belfort; Luiz Vicente Rizzo
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

6.  Diagnostic value of specific local antibody production and nucleic acid amplification technique-nested polymerase chain reaction (nPCR) in clinically suspected ocular toxoplasmosis.

Authors:  B Mahalakshmi; K Lily Therese; H N Madhavan; J Biswas
Journal:  Ocul Immunol Inflamm       Date:  2006-04       Impact factor: 3.070

7.  Patterns of uveitis in a tertiary eye care center in Iran.

Authors:  Masood Soheilian; Kumars Heidari; Shahin Yazdani; Mohsen Shahsavari; Hamid Ahmadieh; Mohammad Dehghan
Journal:  Ocul Immunol Inflamm       Date:  2004-12       Impact factor: 3.070

Review 8.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

Review 9.  Atypical presentations of ocular toxoplasmosis.

Authors:  Justine R Smith; Emmett T Cunningham
Journal:  Curr Opin Ophthalmol       Date:  2002-12       Impact factor: 3.761

10.  Detection of Toxoplasma gondii DNA by PCR in blood samples collected from pregnant Saudi women from the Aseer region, Saudi Arabia.

Authors:  Saad M Bin Dajem; Mona A Almushait
Journal:  Ann Saudi Med       Date:  2012 Sep-Oct       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.